BSc (Hons), PGCert MedEd, PGDip EAM, NMP
Milton Keynes University Hospital NHS Foundation Trust
Fonthill House (Harry Park) Nursing Home
Lead Research Nurse at MKUH for the ORION 4 study (A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People with Cardiovascular Disease).
I’ve worked as a Research Nurse for 4 years at MKUH, and 2 years at CCVTM at the Churchill Hospital, Oxford, working on the HIV-Core 001 and 002 HIV Vaccine trials with Prof Lucy Dorrell. During my nursing career I have worked in A&E, Neuro ITU and GUM/Family Planning, in the NHS, the charitable sector and the British Army.
At MKUH I am PI for the Priest study and Falcon C-19 Covid-19 studies and am lead nurse for the A&E and Sexual Health research portfolios.
I am currently doing my Professional Doctorate in Public Health, exploring how a hospital attendance is experienced by transgender patients, their significant others and their healthcare delivery staff at MKUH.
I work as Research Nurse Consultant for Fonthill Nursing Home, helping to ensure that their practice is evidence-based and current.
Rose, A. (2021) A crisis does not automatically create team glue. Nursing Times. 08 March 2021
Hayton, E.J., Rose, A., Ibrahimsa, U., Del Sorbo, M., Capone, S., Crook, A., Black, A.P., Dorrell, L. and Hanke, T., (2014). Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PloS one, 9(7), p.e101591.
Borthwick, N., Ahmed, T., Ondondo, B., Hayes, P., Rose, A., Ebrahimsa, U., Hayton, E.J., Black, A., Bridgeman, A., Rosario, M. and Hill, A.V., (2014). Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Molecular therapy, 22(2), pp.464-475.
Morón-López, S., Hancock, G., Puertas, M.C., Rose, A., Salgado, M., Hayton, E.J., Morgan, C., Angus, B., Yang, H., Hanke, T. and Dorrell, L., (2014). Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV Conserved Region Vaccine, MVA. HIVconsv, in HAART-treated Subjects. AIDS Research and Human Retroviruses, 30(S1), pp.A190-A190.
Ahmed, T., Borthwick, N., Yang, H., Hancock, G., Yorke, L., Ebrahimsa, U., Rose, A., Black, A., Hayton, E., McMichael, A. and Dorrell, L., (2012). Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1. Retrovirology, 9(2), pp.1-1.
Borthwick, N.J., Ahmed, T., Rose, A., Ebrahimsa, U., Black, A., Hayton, E., Yang, H., Hancock, G., Campion, S., Frahm, N. and Colloca, S., (2012). Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial. Retrovirology, 9(2), pp.1-1.
Dorrell, L., Williams, P., Suttill, A., Brown, D., Roberts, J., Conlon, C., Hanke, T. and McMichael, A., (2007). Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA. HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine, 25(17), pp.3277-3283.
Ondondo, B., Yang, H., Dong, T., de Gleria, K., Suttill, A., Conlon, C., Brown, D., Williams, P., Bowness, P., Rowland-Jones, S.L. and Hanke, T., (2006). Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen. Retrovirology, 3(1), pp.1-1.
Sutherland, R., Yang, H., Scriba, T.J., Ondondo, B., Robinson, N., Conlon, C., Suttill, A., McShane, H., Fidler, S., McMichael, A. and Dorrell, L., (2006). Impaired IFN-γ-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. Aids, 20(6), pp.821-829.
Dorrell, L., Yang, H., Ondondo, B., Dong, T., di Gleria, K., Suttill, A., Conlon, C., Brown, D., Williams, P., Bowness, P. and Goonetilleke, N., (2006). Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. Journal of virology, 80(10), pp.4705-4716.
Ondondo, B.O., Yang, H., Dong, T., di Gleria, K., Suttill, A., Conlon, C., Brown, D., Williams, P., Rowland‐Jones, S.L., Hanke, T. and McMichael, A.J., (2006). Immunisation with recombinant modified vaccinia virus Ankara expressing HIV‐1 gag in HIV‐1‐infected subjects stimulates broad functional CD4+ T cell responses. European journal of immunology, 36(10), pp.2585-2594.
Dorrell, L., Yang, H., Iversen, A.K., Conlon, C., Suttill, A., Lancaster, M., Dong, T., Cebere, I., Edwards, A., Rowland-Jones, S. and Hanke, T., (2005). Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. Aids, 19(12), pp.1321-1323.
Dorrell, L., Yang, H., Conlon, C., Suttill, A., Lancaster, M., Edwards, A., Rowland-Jones, S., Hanke, T. and McMichael, A., (2003). A Pilot Study of the Safety and Immunogenicity of An HIV-1 Clade a Gag/Multiepitope DNA Vaccine, pTHr. HIVA, in HIV-1 Seropositive Subjects Receiving Highly Active Antiretroviral Therapy. Clinical Science, 104(s49), pp.54P-54P.
Stirrup, O.T., Asboe, D., Pozniak, A., Sabin, C.A., Gilson, R., Mackie, N.E., Tostevin, A., Hill, T., Dunn, D.T., UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort and Chadwick, D., (2020). Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation. HIV medicine, 21(5), pp.309-321.